Guggenheim raises ABBV target to $288 from $261Guggenheim 上调目标价 艾伯维 (ABBV)：$261 → $288
English Version
On August 4, 2026, Guggenheim raised its price target for AbbVie (ABBV), a $430.7B biopharmaceutical company, from $261 to $288, a 10.3% upward revision. This adjustment only modified the price target and did not include a concurrent rating change, making it a pure valuation update for market participants tracking sell-side analyst sentiment on the stock.
This revision aligns with AbbVie’s recently released second-quarter 2026 earnings, which beat both top- and bottom-line consensus estimates. On July 31, 2026, the company reported adjusted EPS of $3.65, exceeding the Street’s $3.61 forecast, and total revenue of $16.99B, above the expected $16.80B. This marks the second consecutive quarter where AbbVie has outperformed earnings and revenue estimates. Guggenheim’s adjustment coincided with AbbVie filing a Form 424B5 with the SEC, though the filing did not explicitly reference the analyst target update.
As of December 31, 2025, 73.8% of AbbVie’s float was held by institutional investors across 4,183 reporting holders, an increase of 187 holders from the prior period, with 2,011 institutions increasing their positions, reflecting broad institutional confidence in the stock.
Follow-up markers
1. Track whether other sell-side firms will follow with matching price target or rating revisions for AbbVie;
2. Monitor AbbVie’s third-quarter 2026 earnings report due October 30, 2026;
3. Confirm whether Guggenheim will publish additional details on the drivers of its price target update.
This signal represents only one firm’s valuation model adjustment, does not reflect official company operational changes, and is not a recommendation to buy, sell, or hold any security.
中文版本
2026年8月4日，古根海姆（Guggenheim）将市值4307亿美元的生物制药公司艾伯维（ABBV）的目标价从261美元上调至288美元，上调幅度达10.3%，本次调整仅涉及目标价修订，未同步调整公司评级，属于纯估值逻辑更新。
本次目标价上调可与艾伯维近期公布的2026年第二季度财报形成呼应：2026年7月31日披露的财报显示，公司当季每股收益为3.65美元，超出市场预期的3.61美元；营收达169.9亿美元，高于市场预期的168.04亿美元，连续两个季度超出营收和盈利预期。古根海姆本次调整当日，艾伯维同步提交了SEC 424B5号文件，但该文件未直接提及本次券商估值调整的触发细节。
截至2025年12月31日，艾伯维流通股的73.8%由机构投资者持有，共有4183家机构持仓，较此前增加187家，其中2011家机构增持了仓位，反映出机构对该股的长期配置意愿。
后续关注
1. 追踪其他券商是否会跟进调整艾伯维的目标价或评级；
2. 关注艾伯维将于2026年10月30日公布的第三季度财报表现；
3. 确认古根海姆是否会在后续研报中披露本次目标价上调的具体驱动因素。
该信号仅代表单家机构的估值判断，不构成任何投资建议，也并非艾伯维自身业务的实质性变动公告。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。